Publications and Lectures

Dr. Richard G. Stock Publications and Lectures:

Dr. Stock has over 130 medical publications. Click Here to view PubMed publications.

Publications and Lectures
Publications:

1. Stock RG, Mychalczak B, Armstrong JG, Curtin JP, Harrison LB: The importance of brachytherapy technique in the treatment of primary carcinoma of the vagina. Int J Radiat Oncol Biol Phys. 24:747-753; 1992.

2. Stock RG, Chen ASJ, Flickinger JC, Kalnicki S, Seski J: Node positive cervical cancer: Impact of pelvic irradiation and patterns of failure. Int J Radiat Oncol Biol Phys 31:31-36, 1995.

3. Stock RG, Chen ASJ, Seski J: A thirty-year experience in the management of primary carcinoma of the vagina: Analysis of prognostic factors and treatment modalities. Gynecol Oncol 56:45-52, 1995.

4. Stock RG, Stone NN, Wesson MF, DeWyngaert JK: A modified technique allowing interactive ultrasound guided three- dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys. 32:219-225, 1995.

5. Stone NN, Ramin SA, Wesson MF, Stock RG, Unger P, Klein G: Laparoscopic pelvic lymph node dissection combined with real time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate. J Urol 153:1555-1560, 1995.

6. Unger PD, Hoon V, Stone NN, Liu Z, Theise N, Stock RG, Gil J: Computerized interactive morphometry in the differential diagnosis of irradiated prostates – Anal Quant Cytol Histol 17:100-108,1995.

7. Stock RG, Stone NN, Iannuzzi C, Unger P: Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: Implications for patient selection in the radiotherapeutic management of prostate cancer. Int J Radiat Oncol Biol Phys 33:815-821, 1995.

8. Stone NN, Stock RG, Iannuzzi CM, Unger P: Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in men with localized carcinoma of the prostate. J Urol 154:1392-1396, 1995.

9. Stone NN, Stock RG: Brachytherapy for prostate cancer: Real- time three-dimensional interactive seed implantation. Tech Urol 1:72 -80, 1995.

10. Stone NN, Stock RG, DeWyngaert JK, Tabert A: Prostate brachytherapy: Improvements in prostate volume measurements and dose distribution using interactive ultrasound guided implantation and 3-D dosimetry. Radiat Oncol Investig 3:185-195, 1995.

11. Stock RG: Locoregional therapies for early stage prostate cancer. Oncology 9:803-816, 1996.

12. Stock RG, Stone NN, Iannuzzi C: Sexual potency following interactive ultrasound guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 35:267-272, 1996.

13. Stock RG, Stone NN, DeWyngaert JK, Lavagnini P, Unger P: Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate cancer. Cancer 77:2386-2392, 1996.

14. Glajchen N, Shapiro R, Stock RG, Stone NN, Ramos R: CT findings following laparoscopic pelvic lymph node dissection and radioactive seed implantation. Am J Roentgenol 166:1165-1168, 1996.

15. Stock RG, Chen AS, Karasek K: Patterns of spread in node positive cervical cancer: The relationship between local control and distant metastases. Cancer J Sci Am 2:256-262, 1996.

16. Linzer D, Stock RG, Stone NN, Iannuzzi C, Unger P: Seminal vesicle biopsy: Accuracy and implications in patient selection in early stage prostate cancer. Urology 48:757-761, 1996.

17. Yeung N, Shapiro RS, Glajchen N, Stock RG: CT appearance of the Syed-Neblett device for interstitial brachytherapy of gynecologic malignancies. Comput Med Imaging Graph 20:403-406, 1996.

18. Stock RG, Terk M, DeWyngaert JK, Chan K, Stone NN, Dottino P: A new technique for performing Syed-Neblett template interstitial temporary implants for gynecologic malignancies using transrectal ultrasound guidance. Int J Radiat Oncol Biol Phys. 37:819-825, 1997.

19. Unger P., Wang Q, Gordon RE, Stock RG, Stone NN: Localized amyloidosis of the seminal vesicle. Possible association with hormonally treated prostatic adenocarcinoma. Arch Pathol Lab Med 121:1265-1268, 1997.

20. Stone NN, Stock RG, Unger P: Laparoscopic pelvic lymph node dissection for prostate cancer: Comparison of the extended and modified techniques. J Urol 158:1891-1894, 1997.

21. Stock RG, Stone NN: The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Semin Surg Oncol 13:454-469, 1997.

22. Ferrari AC, Stone NN, Eyler JN, Gao M, Mandeli J, Unger P, Gallagher RE, Stock RG: Molecular staging of pelvic lymph nodes increases the detection of micrometastases in high-risk localized prostate cancer patients. J Natl Cancer Inst 89:1498-1504, 1997.

23. Stock RG, Dottino P, Jennings TS, Terk M, DeWyngaert K, Beddoe AM, Cohen C: Enhanced radiosensitization with interferon alpha-2b and cisplatin in the treatment of locally advanced cervical carcinoma. Gynecol Oncol 67:309-315,1997.

24. Baird M, Blasko J, Beyer D, Dattoli M, Grado G, Grimm P, Martinez A, Mate T, Nori D, Porter A, Stock RG, Syed N, Wallner K: American Brachytherapy Society (ABS) survey of current clinical practice for permanent brachytherapy of prostate cancer. Journal of Brachytherapy 13:243-251, 1997.

25. Stock RG, Stone NN, Tabert A, DeWyngaert K: A dose response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41:101-108, 1998.

26. Prestidge BR, Prete JJ, Buchholz TA, Friedland JL, Stock RG, Grimm PD, Bice WS: A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 40:10001-5, 1998.

27. Prete JJ, Prestidge BR, Bice WS, Friedland UL, Stock RG, Grimm PD: A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 39:1001-1009, 1998.

28. Stock RG, Stone NN, Yaghian P: Neoadjuvant androgen suppression and permanent radioactive seed implant in the treatment of T1-T2 prostate cancer. Molecular Urology 2:121-127, 1998.

29. Terk MD, Stock RG, Stone NN: Identification of patients at an increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 160:1379-1382, 1998.

30. Desai J, Stock RG, Stone NN, Iannuzzi C, DeWyngaert JK: Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Investig 6:135-141, 1998.

31. Stone NN, Stock RG, Parikh D, Unger P: Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized pelvic carcinoma of the prostate. J Urol 160:1722-1726, 1998.

32. Stock RG, Ferrari AC, Stone NN: Does pelvic radiation play a role in the management of prostate cancer? Oncology 12:1467-1472, 1998.

33. Lehrer S, Fodor F, Stock RG, Stone NN, Eng C, Song HK, McGovern M: Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer 78:771-773, 1998.

34. Stone NN, Stock RG: Laparoscopic pelvic lymph node dissection for prostate cancer. Mt Sinai J Med 66:26-30, 1999.

35. Iannuzzi C, Stock RG, Stone NN: PSA kinetics following I-125 prostate seed implantation. Radiat Oncol Investig 7:30-35, 1999.

36. Stone NN, Stock RG: Prostate brachytherapy: treatment strategies. J Urol 162:421-426, 1999.

37. Stock RG, Lo YC, Gaildon M, Stone NN: Does prostate brachytherapy treat the seminal vesicles? A Dose Volume histogram analysis of seminal vesicles in patients undergoing combined PD-103 prostate implantation and external beam irradiation. Int J Radiat Oncol Biol Phys 45:385-389,1999.

38. Green S, Stock RG, Greenstein A: Inflammatory bowel disease and rectal cancer: Natural history and implication for radiation therapy. Int J Radiat Oncol Biol Phys 44:835-840,1999.

39. Stone NN, Stock RG: Neoadjuvant hormonal therapy improves outcomes of patients undergoing radioactive seed implant for localized prostate cancer. Mol Urol 3:239-244,1999.

40. Stone NN, Stock RG: Dynamic cystography can replace cystoscopy following prostate seed implantation. Tech Urol 6:112-116, 2000.

41. Nag S., Bice W., DeWyngaert JK, Prestidge B., Stock RG, Yu Y.: The American Brachytherapy Society recommendations for permanent prostate Brachytherapy post-implant analysis. Int J Radiat Oncol Biol Phys. 46:221-230, 2000.

42. Stone NN, Stock RG: Prostate brachytherapy in patients with prostate volumes 50cm3. Dosimetric analysis of implant quality. Int J Radiat Oncol Biol Phys 46:1199-204, 2000.

43. Stock RG, Stone NN, Lo YC: Intraoperative dosimetric representation of the real-time ultrasound guided prostate implant. Tech Urol 6:95-98, 2000.

44. Stone NN, Ratnower E, Stock RG: Prostate brachytherapy: A prior transurethral resection does not increase morbidity following the real-time seed implant method. Tech Urol 6:123-127, 2000.

45. Fang DX, Stock RG, Machac J, Krynyckyi BR, Kim CK, Stone NN. The use of radioimmunoscintigraphy with 111-indium labeled CYT-356 (Prostascint) scan in the evaluation of patients for salvage brachytherapy. Tech Urol 6:146-150, 2000.

46. Lehrer S, McCurdy L, Stock RG, Stone NN, Ng CM. Body mass, age and the APC I1307K allele in Ashkenazi Jewish prostate cancer patients. Cancer Genet Cytogenet 122:131-3, 2000.

47. Stock RG, Stone NN, Lo YC, Malhado N, Kao J, DeWyngaert JK. Post-implant dosimetry for I-125 prostate implants: Definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys 48:899-906, 2000.

48. Crawford ED, Batuello JT, Snow P, Gamito EJ, McLeod DG, Partin AW, Stone N, Montie J, Stock R, Lynch J, Brandt J. The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate cancer. Cancer 88:2105-2109, 2000.

49. Stock RG, Stone NN, Kao J, Iannuzzi C, Unger P. The effect of disease and treatment related factors on biopsy results following prostate brachytherapy: Implications for treatment optimization. Cancer 89:1829-34, 2000.

50. Stone NN, Stock RG, Unger P. Effect of neoadjuvant hormonal therapy on prostate biopsy results after I125 and Pd103 seed implantation. Mol Urol 4:163-170, 2000.

51. Stone NN, Stock RG, Unger P, Kao J. Biopsy results after real-time ultrasound guided transperineal implants for stage T1-T2 prostate cancer. J Endourol 14: 375-380, 2000.

52. Stock RG, Kao J, Stone NN. Penile erectile function following permanent radioactive seed implantation in the treatment of prostate cancer. J Urol 165:436-9, 2001.

53. Snyder KM, Stock RG, Hong SM, Lo YC, Stone NN. Defining the risk of developing grade 2 proctitis following I-125 prostate brachytherapy using a rectal dose volume histogram analysis. Int J Radiat Oncol Biol Phys 50: 335-341, 2001.

54. Nag S, Ciezki JP, Cormack R, Dogget S, DeWyngaert K, Edmunson GK, Stock RG, Stone NN, Yu Y, Zelefsky M. Intraoperative planning and evaluation of permanent prostate brachytherapy: Report of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 51:1422-1430, 2001.

55. Atencio DP, Iannuzzi CM, Stock RG, Rosenstein BS. Screening breast cancer patients for ATM mutations and polymorphisms using denaturing high performance liquid chromatography. Environ Molec Mutagenesis 38:200-208, 2001.

56. Lehrer S, Diamond EJ, Stagger S, Stone NN, Droller MJ, Stock RG. Association between serum triiodothyronine (t3) level and risk of disease recurrence in men with localized prostate cancer. Prost Ca Prost Dis 4:232-234, 2001.

57. Lee L, Stock RG, Stone NN. The impact of hormonal therapy in the management of intermediate to high risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 52:444-452, 2002.

58. Iannuzzi CM, Atencio DP, Green S, Stock RG, Rosenstein BS. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys 52:604-611, 2002.

59. Stock RG, Stone NN. The importance post-implant dosimetry in permanent prostate brachytherapy. Eur Urol 41: 434-439, 2002.

60. Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol 41: 427-433, 2002.

61. Lehrer S, Stone NN, Droller MJ, Stock RG. Association between American Urologic Association Urinary Symptom Score and disease stage in men with localized prostate cancer. Urol Oncol 7:73 – 76, 2002.

62. Stock RG, Stone NN. Preliminary toxicity and PSA response of a phase I/II trial of neoadjuvant hormonal therapy, Pd-103 brachytherapy and 3-D conformal external beam irradiation in the treatment of locally advanced prostate cancer. Brachytherapy 1: 2 – 10, 2002.

63. Ferrari AC, Stone NN, Stock RG, Bednar M, Essessee I, Singh H, Baldwin I, Mandeli J. 13 cis-retinoic acid (Isotretinoin) and complete androgen blockade in advanced hormone naïve prostate cancer patients. Report of a phase II randomized study. J Clin Oncol 20: 538 – 544, 2002.

64. Stock RG, Stone NN, Dahlal M, Lo YC. What is the optimal dose for I-125 prostate implants? A dose response analysis of biochemical control, post-treatment biopsies and long-term urinary symptoms. Brachytherapy 1: 83-89, 2002.

65. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG. Increased serum insulin associated with increased risk of prostate cancer recurrence. The Prostate 50: 1-3, 2002.

66. Nag S, Ellis RJ, Merrick GS, Bahnson R, Vicini F, Wallner K, Stock R. American Brachytherapy Society recommendations for reporting morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 54: 462-470, 2002.

67. Lehrer S, Diamond E, Stone NN, Droller M, Stock RG. Serum Triiodothyronine (t3) is increased in men with prostate cancer and benign prostatic hypertrophy. J Urol 168: 2431-2433, 2002.

68. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. Br J Cancer 87: 726 – 728, 2002 .

69. Stock RG, Stone NN, Cesaretti J. Prostate specific antigen bounce following prostate seed implantation for localized prostate cancer: Descriptions and implications. Int J Radiat Oncol Biol Phys 56: 448-453, 2003.

70. Stone NN, Roy J, Lo YC, Stock RG. Prostate gland motion and deformation caused by needle placement during brachytherapy. Brachytherapy 1: 154-160, 2002.

71. Lehrer S, Diamond EJ, Droller MJ, Stone NN, Stock RG. Insulin -like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced stage prostate cancer. JNCI 94: 1893-1894, 2002.

72. Lehrer S, Roboz J, Holland JF, Stone NN, Droller MJ, Stock RG. A 17.5 kda protein in the serum of men with prostate cancer is increased in early stage. Br J Urol (in press).

73. Cesaretti J, Stone NN, Stock RG. Urinary flare following prostate brachytherapy. Int J Radiat Oncol Biol Phys 56: 1085 – 1092, 2003.

74. Lehrer S, Diamond E, Stone NN, Droller MJ, Stock RG, Stone M, Bajwa A, Kornreich R. Elevated serum triiodothyronine (t3) in Ashkenazi Jewish prostate cancer patients carrying the I1307K allele of the APC (adenopolyposis coli) gene. Urol Oncol 21: 101-104, 2003.

75. Kollmeier MA, Stock RG, Stone N. Biochemical outcomes following prostate brachytherapy with minimum of 5 year follow-up: The importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57: 645 – 653, 2003.

76. Stone NN, Hong S, Lo YC, Howard V, Stock RG. Comparison of intraoperative dosimetric implant representation with post-implant dosimetry in patients receiving prostate brachytherapy. Brachytherapy 2: 17-25, 2003.

77. Stone NN, Stock RG. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after I-125 prostate brachytherapy. Brachytherapy 2: 32-39, 2003.

78. Stone NN, Stock RG. Practical considerations in permanent brachytherapy for localized adenocarcinoma of the prostate. Urol Clin North Am 30(2):351-62, 2003.

79. McNeely LK, Stone NN, Pressoer J, Chircus JH, Stock RG. Influence of prostate volume on dosimetry results in real-time I1-25 seed implantation. Int J Radiat Oncol Biol Phys 58: 292 – 299, 2004.

80. Lehrer S, Roboz J, Ding H, Zhao S, Diamond EJ, Holland JF, Stone NN, Droller MJ, Stock RG. Putative protein markers in the sera of men with prostatic neoplasms. British J Urol 92: 223 – 225, 2003.

81. Stock RG, Cahlon C, Cesaretti JA, Kollmeier MA, Stone NN. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 59: 1352 – 1359, 2004.

82. Cesaretti JA, Stone NN, Stock RG. Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis. Int J Radiat Oncol Biol Phys. 60: 248-253, 2004.

83. Lehrer S, Stone NN, Stock RG. Prostate cancer in a large prostate is associated with a decreased prostate specific antigen failure rate after brachytherapy. J Urol 173: 79-81,2005

84. Kollmeier MA, Stock RG, Cesaretti J, Stone NN. Urinary morbidity following postbrachytherapy transurethral resection of the prostate. J Urol 173:808-807, 2005.

85. Stone NN, Stock RG, Unger P. Intermediate-term Biochemical-free Progression and Local Control Following I-125 Brachytherapy for Prostate Cancer. J Urol 173: 803-807.

86. Cesaretti JA, Stock RG, Lehrer S, Atencio D, Bernstein JL, Stone NN, Wallenstein S, Loeb K, Kollmeier M, Smith M, Rosenstein B. ATM sequence variants are predictive of adverse radiotherapy among patients treated for prostate cancer. Int J Radiat Oncol Biol Phys 61: 196-202, 2005.

87. Stone NN, Stock RG. Reduction of Pulmonary Migration of Permanent Interstitial Sources in Patients Undergoing Prostate Brachytherapy” Urology 66: 119-123, 2005.

88. Lehrer S, Diamond EJ, Mamakind B, Droller M, Stone NN, Stock RG C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int 95(7):961-2, 2005.

89. Lehrer S, Diamond EJ, Stone NN, Stock RG. Serum thyroid-stimulating hormone is elevated in men with Gleason 8 prostate cancer. BJU 96: 328-329, 2005.

90. Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and post-treatment biopsy results. Int J Radiat Oncol Biol Phys 64(2):527-33, 2006.

91. Stock RG, Cesaretti JA, Stone NN. Disease-specific survival following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys 64(3):810-6, 2006.

92. Crook JM, Potters L, Stock RG, Zelefsky MJ. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk. Brachytherapy. 2005;4(3):186-94.

93. Andreassen CN, Overgaard J, Alsner J, Overgaard M, Herskind C, Cesaretti JA, Atencio DP, Green S, Formenti S, Stock RG, Rosenstein BS. ATM sequence variants and risk of radiation induced subcutaneous fibrosis after post-mastectomy radiotherapy. Int J Radiat Oncol Biol Phys 64(3):776-83, 2006.

94. Ferrari AC, Stone NN, Kurek R, Mulligan E, McGregor R, Stock R, Unger P, Tunn U, Kaisary A, Droller M, Hall S, Renneberg H, Livak KJ, Gallagher RE, Mandeli J. Molecular load of pathologically-occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol 24(19):3081-8, 2006.

95. Peters C, Cesaretti JA, Stone NN, Stock RG. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. Int J Radiat Oncol Biol Phys 66(2):424-9, 2006.

96. Stock RG, Ho A, Cesaretti JA, Stone NN. Changing the patterns of failure for high risk prostate cancer by optimizing local control. Int J Radiat Oncol Biol Phys 66(2):389-94, 2006.

97. Lehrer S, Cesaretti J, Stone NN, Stock RG. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and increased pre-implant urinary symptoms. BJU Int. 98(5):979-81, 2006.

98. Zagar TM, Stock RG, Cesaretti JA, Stone NN. Assessment of post-brachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS. Brachytherapy 6(1):26-33, 2007.

99. Ho A, Burri R, Cesaretti JA, Stone NN, Stock RG. Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined Pd-103 implantation and external beam radiation for T3c prostate cancer. Brachytherapy 6(1):38-43, 2007.

100. Stone NN, Stock RG. Long-term urinary, sexual and rectal morbidity in patients treated with I-125 prostate brachytherapy followed for a minimum of 5 years. Urology 69: 338-342, 2007

101. Schiff JD, Bar Chama N, Cesaretti J, Stock R. Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function. BJU 98:1255, 2006.

102. Frank SJ, Grimm PD, Sylvester JE, Merrick S, Davis BJ, Zietman A, Moran BJ, Beyer DC, Roach M, Clark DH, Stock RG, Lee WR, Michalski JM, Wallner KE, Hurwitz M, Potters L, Kuban DA, Prestidge BR, Vera A, Hathaway S, Blasko JC. Interstitial implant alone or in combination with external beam radiation therapy for intermediate – risk prostate cancer: A survey of practice patterns in the United States. Brachytherapy 6: 2-8.

103. Stone NN, Stock RG. The effect of brachytherapy, external beam irradiation, and hormonal therapy on prostate volume. J Urol 177: 1925-1928, 2007.

104. Ho AY, Atencio DP, Peters S, Stock RG, Formenti SC, Cesaretti JA, Green S, Haffty B, Drumea K, Leitzin L, Kuten A, Azria D, Ozsahin M, Overgaard J, Andreassen CN, trop CS, Park J, rosenstein BS.Genetic predictors of adverse radiotherapy effects: the Gene-PARE project.
Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):646-55.

105. Cesaretti JA, Stock RG, Atencio DP, Peters S, Peters CA, Burri RJ, Stone NN, Rosenstein BS. A genetically determined dose response relationship predicts for rectal bleeding among patients treated with prostate brachytherapy. Int J Radiat Oncol Biol Phys Int J Radiat Oncol Biol Phys. 2007 ;68:1410-6.

106. Cesaretti JA, Stock RG, Stone NN. Impact of low dose rate prostate brachytherapy on the sexual health of 131 men with optimal pre-treatment sexual function: an analysis at seven year minimal follow-up. BJU Int. 2007 ;100:362-367.

107. Ho AY, Fan G, Atencio DP, Green S, Formenti S, Haffty BG, Iyengar P, Bernstein JL, Stock RG, Cesaretti JA, Rosenstein BS. Possession of ATM Sequence Variants as a Predictor for Late Normal Tissue Responses in Breast Cancer Patients Treated with Radiotherapy. Int J Radiat Oncol Biol Phys Int J Radiat Oncol Biol Phys 2007 69:677-684.

108. Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Fern PA, Kattan MW, Stock RG. Customized dose prescriptions for permanent prostate brachytherapy: Insights from a multicenter analysis of dosimetry outcomes. In J Radiat Oncol Biol Phys 2007 69: 1472 – 1477.

109. Stone NN, Stock RG, White I, Unger P. Patterns of local failure following prostate brachytherapy.
J Urol 177 :1759-63; 2007

110. Kao J, Stone NN, Lavaf A, Dumane V, Cesaretti JA, Stock RG. (125)I monotherapy using D90 implant doses of 180 Gy or greater. Int J Radiat Oncol Biol Phys. 2008; 70:96-101.

112. Peters CA, Stock RG, Cesaretti JA, Atencio DP, Peters S, Burri R, Stone NN, Osterer H, Rosenstein BS. TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy.
Int J Radiat Oncol Biol Phys. 2008 70:752-759.

113. Stock RG, Cesaretti JA, Stone NN. Distant and local recurrence in patients with biochemical failure following prostate brachytherapy. Brachytherapy 7: 217-222, 2008.

114. Peters C, Stock RG, Blacksburg S, Stone NN,. The Effect of Family History on Outcome in Patients Treated with Definitive Brachytherapy for Clinically Localized Prostate Cancer. . Int J Radiat Oncol Biol Phys 2009; 73: 24-29.

115. Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Fern PA, Kattan MW, Stock RG. Multicenter Analysis of Impact of High Biological Effective Dose (BED) on Biochemical Failure and Survival Outcomes in Patients with Gleason score 7-10 Prostate Cancer Treated by Permanent Prostate Brachytherapy. . Int J Radiat Oncol Biol Phys 2009; 73: 1472-1477.

116. Burri RJ, Stock RG, Cesaretti JA, Atencio DP, Peteres S, Peters CA, Fan G, Stone NN, Rosenstein BS. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiation Research 170: 49-59. 2008.

117. Solan A, Cesaretti JA, Stone NN, Stock RG. There is No Correlation Between Erectile Dysfunction and Dose to Penile Bulb and Neurovascular Bundles Following Real-Time Low-Dose Rate Prostate Brachytherapy International Journal of Radiation Oncology, Biology, Physics. . Int J Radiat Oncol Biol Phys 2009; 73: 1468 – 1474.

118. Lehrer S, Montazema A, Ramanathan L, Pessin – Minsleym, Pfail J, Stock RG, Kogan R. Normal serum bone markers in bisphosphonate induced osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106: 389-391, 2008

119. Stock RG, Klein TJ, Cesaretti JA, Stone NN. Prognostic Significance of the 5-Year PSA Value for Predicting Prostate Cancer Recurrence Following Brachytherapy Alone and in Combination with Hormonal Therapy and/or External Beam Irradiation . Int J Radiat Oncol Biol Phys 2009: 74: 753-758.

120. Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG. Radiation dose predicts for biochemical control in intermediate risk prostate cancer patients treated with low dose rate brachytherapy. Int J Radiat Oncol Biol Phys 2009 :75: 16-22.

121. Kao J, Packer S, Linh Vu H, Schwartz ME, Sung MW, Stock RG, Lo YC, Huang D, Chen SH, Cesaretti JA. Phase I study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 2009: 115: 3571-3580.

122. Stock RG, Cesaretti JA, Hall SJ, Stone NN. Outcomes for patients with high grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJUI 2009: 104; 1631 -1636.

123. Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg. 2009 Jan;67(1):159-61.

124. Potters L, Roach M 3rd, Davis BJ, Stock RG, Ciezki JP, Zelefsky MJ, Stone NN, Fearn PA, Yu C, Shinohara K, Kattan MW. Postoperative Nomogram Predicting the 9-Year Probability of Prostate Cancer Recurrence After Permanent Prostate Brachytherapy Using Radiation Dose as a Prognostic Variable. Int J Radiat Oncol Biol Phys. 2009 Jun 17.

125. Burri R, Stone NN, Stock RG. Long term outcomes and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2009: 77; 1338 – 1344.

126. Burri R, Ho A, Stone NN, Stock RG . Young Men Have Equivalent Biochemical Outcomes Compared To Older Men After treatment With Brachytherapy For Prostate Cancer. Int J Radiat Oncol Biol Phys 2010: 77; 1315 – 1321.

127. Stone NN, Stock RG, Cesaretti JA, Unger P. Local Control Following Permanent Prostate Brachytherapy: Effect of High Biologically Effective Dose on Biopsy Results and Oncologic Outcomes. Int J Radiat oncol Biol Phys 2010 : 76; 355 – 360.

128. Stock RG, Yamalachi S, Hall SJ, Sone NN. Impact of Hormonal Therapy on Intermediate Risk Prostate Cancer Patients treated with Combination Brachytherapy and External Beam Irradiation. J Urol 2010: 183; 546 – 550.

129. Stone NN, Stock RG. Do high radiation doses in locally advanced prostate cancer patients treated with Pd-103 implant plus external beam irradiation cause increased urinary, rectal and sexual morbidity. Brachytherapy 2010: 9; 114-118.

130. Stone NN, Marshal D, Cesaretti JA, Stock RG. Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy? J Urol 2010: 183; 546 – 550.

131. Kerns S, Ostrer H, Stock R, William Li, Moore J, Pearlman A, Campell C, Shao Y, Stone, N, Kusnetz L, Rosenstein B. Genome wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African American men following radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1292-300.

132. Carpenter TJ, Forsythe K, Kao J, Stone NN, Stock RG. Outcomes for patients with extracapsular prostate cancer treated with trimodality theapy, including brachytherapy, external beam radiotherapy and hormonal therapy. Brachytherapy. 2011 Jul-Aug;10(4):261-8.

133. Forsythe K, Burri R, Stone N, Stock RG. Predictors of Metastatic Disease After Prostate Brachytherapy. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):645-52. Epub 2011 Dec 2.

134. Stone NN, Gerber NK, Blacksburg S, Stone J, Stock RG. Factors Influencing Urinary Symptoms 10 Years After Permanent Prostate Seed Implantation. J Urol. 2012 Jan;187(1):117-23. Epub 2011 Nov 23.

135. Forsythe K, Blacksburg S, Stone N, Stock RG.Intensity-Modulated Radiotherapy Causes Fewer Side Effects than Three-Dimensional Conformal Radiotherapy When Used in Combination with Brachytherapy for the Treatment of Prostate Cancer. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):630-5. Epub 2011 Nov 16.

136. Ko EC, Stone NN, Stock RG. PSA Nadir of <0.5 ng/mL Following Brachytherapy for Early-Stage Prostate Adenocarcinoma is Associated with Freedom from Prostate-Specific Antigen Failure. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):600-7. Epub 2011 Oct 8.

137. Yamoah K, Stone N, Stock R. Impact of race on biochemical disease recurrence after prostate brachytherapy Cancer. 2011 Dec 15;117(24):5589-600.

138. Stone NN, Stone MM, Rosenstein BS, Unger P, Stock RG. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy.J Urol. 2011 Feb;185(2):495-500.

139. Stock RG, Berkowitz J, Blacksburg SR, Stone NN. Gleason 7 prostate cancer treated with low dose rate brachytherapy: Lack of impact of primary Gleason pattern on biochemical failure. BJU Nov;110(9):1257-61. doi: 10.1111/j.1464-410X.2012.11057.x. Epub 2012 May 9.

140. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.BJU Int. 2012 Feb;109 Suppl 1:22-9. :

141. Snyder KM, Stock RG, Buckstein M, Stone NN. Long-term potency preservation following brachytherapy for prostate cancer. BJU Int. 2012 Jul;110(2):221-5.

142. Buyyounouski MK, Davis BJ, Prestidge BR, Shanahan TG, Stock RG, Grimm PD, Demanes DJ, Zaider M, Horwitz EM. A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update.Brachytherapy. 2012 11: 299-303.

143. Stone NN, Skouteris VM, Stock RG. Biopsy and implantation of the seminal vesicles. Brachytherapy. 2012 Sep-Oct;11(5):334-40. doi: 10.1016/j.brachy.2011.12.008. Epub 2012 Feb 2.

144. Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, Butler WM, Grimm PD, Stone NN, Potters L, Zietman AL, Zelefsky MJ. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012 Jan;11(1):6-19.

145. Diefenbach MA, Mohamed NE, Butz BP, Bar-Chama N, Stock R, Cesaretti J, Hassan W, Samadi D, Hall SJ. Acceptability and preliminary feasibility of an internet/CD-ROM-based education and decision program for early-stage prostate cancer patients: randomized pilot study. J Med Internet Res. 2012 Jan 13;14(1):e6.

146. Tong C, Ko EC, Sung MW, Cesaretti JA, Stock RG, Packer SH, Forsythe K, Genden EM, Schwartz M, Galsky M, Junko O. Phase II Trial of Concurrent Sunitinib and Image-Guided Radiotherapy for Oligometastases. Plos One 2012;7(6):e36979. Epub 2012 Jun 27

147. Buckstein M, Kerns S, Forsythe K, Stone NN, Stock RG. Temporal Patterns of Selected Late Toxicities in Patients Treated with Brachytherapy or Brachytherapy Plus External Beam Radiation for Prostate Adenocarcinoma. BJU 2012 Oct 9. doi: 10.1111/j.1464-410X.2012.11436.x. [Epub ahead of print]

148. Buckstein M, Stone NN, Stock RG. Long Term Outcomes and Toxicity in Patients Treated with Brachytherapy for Prostate Adenocarcinoma Younger than 60 Years of Age at Treatment with Minimum 10 Years Follow Up. Urology. 2013 Feb;81(2):364-8

149. Leapman M, Hall SJ, Stone N, Stock R. Hematuria after prostate brachytherapy. BJU Int. 2013 Jun;111(8):E319-24.

150. Kerns Sl, Stock R, Stone N, Buckstein M, Shao Y, Campbell, Rath L, DeRuyssher D, Lammering G, Hixson R, Cesaretti J, Terk M, Ostrer H, Rosenstein B. A Two stage genome wide association study to identify nucleotide polymorphisms associated with development of erectile dysfunction following radiotherapy for prostate cancer. IJROBP 2012 Sep 26. doi:pii: S0360-3016(12)03389-5. 10.1016/j.ijrobp.2012.08.003. [Epub ahead of print]

151. Kerns SL, Stone NN, Stock RG, Rath L, Ostrer H, Rosenstein BS. A two stage genome wide association study to identify single nucleiotide polymorphisms asoaciated with development of urinary symptoms following radiotherapy for prostate cancer. l J Urol. 2013 Jul;190(1):102-8

152. Stone NN, Stock RG. Prostate brachytherapy in men with gland volume of 100cc or greater: Technique, cancer control and morbidity. Brachytherapy Brachytherapy. 2013 May-Jun;12(3):217-21

153. Price JG, Stone NN, Stock RG. Predictive factors and management of rectal bleeding side effects following prostate cancer brachytherapy. Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):842-7

154. Stock RG, Buckstein M, Liu JT, Stone NN. The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes.
BJU Int. 2013 Jul;112(2):E44-50.

155. Marshall RA, Buckstein M, Stone NN, Stock R. Treatment outcomes and morbidity following definitive brachytherapy with or without external beam radiation for the treatment of localized prostate cancer: 20-Year experience at Mount Sinai Medical Center.
Urol Oncol. 2013 Jun 12. doi:pii: S1078-1439(13)

156. Kerns SL, Stock RG, Stone NN, Blacksburg SR, Rath L, Vega A, Fachal L, Gómez-Caamaño A, De Ruysscher D, Lammering G, Parliament M, Blackshaw M, Sia M, Cesaretti J, Terk M, Hixson R, Rosenstein BS, Ostrer H. Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer.Radiother Oncol. 2013 Jun;107(3):372-6.

157. Mock S, Leapman M, Stock RG, Hall SJ, Stone NN. Risk of Urinary Incontinence Following Post-Brachytherapy Transurethral Resection of the Prostate and Correlation with Clinical and Treatment Parameters. J Urol. 2013 Nov;190(5):1805-181

158. Leapman MS, Stock RG, Stone NN, Hall SJ. Findings at Cystoscopy Performed for Cause After Prostate Brachytherapy. Urology. 2014 Apr 3. pii: S0090-4295(14)00111-3. doi: 10.1016/j.urology.2014.01.031. [Epub ahead

159. Stone NN, Stock RG. 15-Year Cause Specific and All-Cause Survival Following Brachytherapy for Prostate Cancer: Negative Impact of Long-term Hormonal Therapy. J Urol. 2014 Mar 31. pii: S0022-5347(14)03182-6. doi: 10.1016/j.juro.2014.03.094. [Epub ahead of

160. Zelefsky MJ, Shasha D, Branco RD, Kollmeier M, Baser RE, Pei X, Ennis R, Stock R, Bar-Chama N, Mulhall JP. Prophylactic Sildenafil Citrate Improves Selected Aspects of Sexual Function in Men Treated by Radiotherapy for Prostate Cancer.
J Urol. 2014 Mar 3. pii: S0022-5347(14)00355-3. doi: 10.1016/j.juro.2014.02.097. [Epub ahead of

161. Stone NN, Unger Crawford ED, Stock RG. Diagnosis and management of local recurrence after low-dose rate brachytherapy. Brachytherapy 2014: 1538-4721 (epub ahead of print)

162. Ko EC, Liu JT, Stock RG. Association of early PSA failure time with increased distant metastasis and decreased survival in prostate brachytherapy patients. Raditherapy Oncology 2014:110 261-267.

Books and Chapters in Books

Stone NN, Stock RG: “Real Time Interactive Prostate Seed Implantation” in Smith’s Textbook of Endourology. Smith AD (ed.), 1995.

Stock RG: “Vaginal Cancer” in Textbook of Radiation Oncology. Leibel S, Phillips T (eds.), 1998.

Stock RG: “Salvage Brachytherapy” in Radiotherapy for Prostate Cancer. Greco C, Zelefsky M (eds.), 2000.

Stock RG, Eschwege F: “External Beam Irradiation for Localized Prostate Cancer” in Prostate Cancer. Murphy G, Khoury S, Partin A, Denis L (eds.), 2000.

Stock RG, Stone NN. Combined modality therapy with brachytherapy and external beam irradiation in the management of localized prostate cancer in Management of prostate cancer: advances and controversies. Cummings K. (ed.).

Stone NN, Stock RG. Transrectal ultrasound guided permanent prostate seed implantation: an updated technique using real-time imaging and intraoperative dosimetric adjustment. In Minimally invasive surgery. Eds Kaplin, Partin, Gomella, 2002 (in press)

Stock RG, Green S. “Vaginal Cancer” in Textbook of Radiation Oncology. Leibel S, Phillips T (eds), 2004.

Green S , Stock RG,. “Vaginal Cancer” in Textbook of Radiation Oncology. Leibel S, Phillips T (eds), 2009 (in press.

 
INVITED LECTURES/PRESENTATIONS:
 

  • Armstrong JG, Stock RG: Current issues in non-small cell lung cancer. New York Roentgen Society Annual Meeting, Spring 1992.
  • Stock RG: High dose rate brachytherapy in the treatment of lung cancer. Pulmonary Grand Rounds. Mount Sinai Hospital, October 1994.
  • Stock RG: Brachytherapy for prostate cancer: Results from Mount Sinai Hospital (Invited speaker). American Brachytherapy Society 17th Annual Winter Meeting. Fort Myers, Florida, December 10, 1994.
  • Stock RG: The use of hormonal therapy prior to brachytherapy in the treatment of prostate cancer. Schering Oncology speaker update. Dallas, Texas, December 1994.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Northwest Hospital Center. Randallstown, Maryland. September 23, 1995.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Holy Cross Hospital, Silver Spring, Maryland. September 23, 1995.
  • Stock RG: Gynecologic oncology oral presentation session (Moderator) American Society of Therapeutic Radiation and Oncology 37th Annual Scientific Meeting. Miami Beach, Florida, October 9, 1995.
  • Stock RG: Brachytherapy in vaginal cancer (Invited speaker). American Brachytherapy Society, 18th Annual Winter Meeting. Scottsdale, Arizona, December 12, 1995.
  • Stock RG: Prostate Brachytherapy: Isotope and patient selection, treatment planning, and combined external irradiation with implantation (Invited speaker). New strategies in the management of T1-T3 carcinoma of the prostate. Mount Sinai School of Medicine, CME accredited program. Scottsdale, Arizona, February 9, 1996.
  • Stock RG: Interactive ultrasound guided seed implantation: Treatment results and morbidity (Invited speaker). New strategies in the management of T1-T3 carcinoma of the prostate. Mount Sinai School of Medicine, CME accredited program. Scottsdale, Arizona, February 10, 1996.
  • Stock RG: Salvage radiation therapy (Invited speaker). New strategies in the management of T1-T3 carcinoma of the prostate. Mount Sinai School of Medicine, CME accredited program. Scottsdale, Arizona, February 10, 1996.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. John T. Mather Memorial Hospital, Port Jefferson, New York. April 27, 1996.
  • Stock RG: Prostate implants (Invited speaker). New York Roentgen Society. Spring conference. New York, New York, May 2, 1996.
  • Stock RG: Comparison of treatment modalities for early stage prostate cancer (Invited speaker). Community General Hospital, Harris, New York. Mount Sinai Teaching Day, May 14, 1996.
  • Stock RG: Comparison of treatment modalities for early stage prostate cancer (Invited speaker). Union Health Center Mount Sinai Teaching Day. New York, New York, May 17, 1996.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. HCA Health Service of Virginia, Reston Hospital Center, Reston, Virginia. June 29, 1996.
  • Stock RG: Interactive ultrasound guided transperineal prostate implantation. Urological Surgery Motion Picture Session. American College of Surgeons 82nd Annual Clinical Congress. San Francisco, California, October 8, 1996.
  • Stock RG: Brachytherapy and the use of neoadjuvant androgen suppression in the treatment of prostate cancer. New strategies in the management of locally advanced prostate cancer: Optimal use of hormonal manipulation. ASTRO symposium. Los Angeles, California, October 28, 1996.
  • Stock RG: Neoadjuvant combination hormonal therapy and radiation therapy in the treatment of prostate cancer (Invited speaker). Symposium, Society of Black Urologists of Maryland, monthly meeting. Bethesda, Maryland, November 4, 1996.
  • Stock RG: Combination hormonal therapy and radiation therapy in the treatment of prostate cancer (Invited speaker). Urology Grand Rounds, Washington Hospital Center. Bethesda, Maryland. November 5, 1996.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Medcenter One. Bismarck, ND. November 9, 1996.
  • Stock RG: Principles of Prostate Brachytherapy. CME accredited program. Shadyside Hospital. Pittsburgh, Pennsylvania. November 16, 1996.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Shadyside Hospital, Pittsburgh, Pennsylvania. November 16, 1996.
  • Stock RG: The use of neoadjuvant hormonal therapy in combination with radiation therapy in the treatment of prostate cancer (Invited speaker). Walt Disney Memorial Cancer Institute. Orlando, Florida, November 21, 1996.
  • Stock RG: Prostate brachytherapy: Interactive ultrasound guided technique and treatment results. CME accredited symposium, Baptist Hospital. Nashville, Tennessee, November 23, 1996.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Baptist Hospital, Inc. Nashville, Tennessee. November 23, 1996.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Baptist Memorial Hospital, Memphis, Tennessee. February 22, 1997.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. 2/23/97 – Baptist Memorial East, Memphis, Tennessee. February 23, 1997.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. St. Joseph Hospital, Lancaster, Pennsylvania. March 22, 1997.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Maryview Medical Center, Portsmouth, Virginia. April 26, 1997.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Northwest Medical Center, Randallstown, Maryland. August 14, 1997.
  • Stock RG: Innovations in the diagnosis and management of prostate carcinoma: Radiation therapy for locally advanced prostate cancer. CME accredited. Opryland Hotel. Nashville, Tennessee, August 22-23, 1997.
  • Stock RG: Prostate brachytherapy course. Lecturer: Results following I-125 implants, interactive ultrasound technique, combined EBRT, implant and hormonal therapy. Mount Sinai CME accredited course. Scottsdale, Arizona, September 5-6, 1997.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Pinnacle Health Hospitals, Harrisburg, Pennsylvania. September 17, 1997.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Glen Falls Hospital, Glens Falls, New York. September 20, 1997.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Riverside Medical Center, Kankakee, Illinois, September 21, 1997.
  • Stock RG: Urology update symposium: Rising PSA after failed local therapy. CME accredited course. Cleveland, Ohio, October 4, 1997.
  • Stock RG: Update on advances in prostate brachytherapy. Urology Grand Rounds. October 13, 1997.
  • Stock RG: Combining old and new strategies in managing prostate cancer. Brachytherapy: Revival of a radiotherapeutic option. CME accredited symposium. Orlando, Florida, October 20, 1997.
  • Stock RG: Advanced prostate cancer: Redefining the challenge. Radiation therapy for recurrent prostate cancer (Invited speaker). CME accredited course. St. Petersburg, Florida. November 2, 1997.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Rex Healthcare. Raleigh, North Carolina. February 7, 1998.
  • Stock RG: Combined use of hormonal therapy and brachytherapy. Brachytherapy and New Therapeutic Strategies in the Treatment of Prostate Cancer. CME Accredited Course. Scottsdale, Arizona, March 5-7, 1998.
  • Stock RG: Hormonal therapy and brachytherapy. 3rd International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer. Boston, MA, March 11-12, 1998.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. St. Lukes Health System, Sioux City, Iowa. March 21, 1998.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Penn State Geisinger Clinic (dba) Hershey Medical Center, Hershey, Pennsylvania. June 6, 1998.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Penn State Geisinger Clinic (dba) Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania. June 14, 1998.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Danbury Hospital, Danbury, Connecticut. November 4, 1998.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Reading Hospital, West Reading, Pennsylvania. April 18, 1999.
  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. 5/22/99 – Pottsville Hospital and Warne Clinic, Pottsville, Pennsylvania. May 22, 1999.
  • Stock RG: Use of post-op RT for arising PSA following local therapy. New York Roentgen Society Spring Conference. New York, New York, May, 1999.
 

  • Stock RG: Co-Director of Didactic Sessions on Principles of Prostate Brachytherapy. Phelps County Regional Medical Center, Rolla, Missouri. June 7, 1999.
  • Stock RG: Advances in post-implant dosimetry. 2nd International Congress on Prostate Cancer. Paris, France, June 25,1999.
  • Stock RG: Advances in prostate brachytherapy. Co-director: CME accredited Course. Scottsdale, Arizona, September 1999.
  • Stock RG: Importance of post-implant dosimetry in prostate brachytherapy. 1st International Conference on Prostate Brachytherapy. Amsterdam, Holland, October 14, 1999.
  • Stock RG, Lepor H. Presentation at the Great Prostate Cancer Debate. Dematteis Cancer Center. Hempstead, New York, March 13, 2000.
  • Stock RG. Invited Speaker. Spring Meeting of the NY Roentgen Society. Radiation therapy for early stage prostate cancer. The New York Academy of Medicine, New York, New York, April 14, 2000.
  • Stock RG. Presentation at ASTRO symposium on intraoperative planning and dosimetry for prostate implantation. Mount Sinai technique of intraoperative dosimetry. Boston, Massachusetts, October 24, 2000.
  • Stock RG. Co-Director and presenter at the 6th Annual Prostate Cancer Symposium. CME Accredited course. Scottsdale, Arizona, February 22-24, 2001.
  • Stock RG. New developments in prostate brachytherapy. Oncology lecture series. St. Barnabas Hospital, Livingston, New Jersey, March 7, 2001.
  • Stock RG. Co-Director and presenter at the 7th Annual Prostate Cancer Symposium. CME Accredited course. Scottsdale, Arizona, March, 2002.
  • Stock RG. Invited speaker. Seattle Prostate Institute Annual Advanced Brachytherapy Meeting. Importance of post-implant dosimetry. Urinary symptoms associated with brachytherapy. Dose response data.. CME accredited course. Seattle, WA. April 12 – 13, 2002.
  • Stock RG. Invited Speaker. Spring Meeting of the NY Roentgen Society. Brachytherapy for prostate cancer. New York, New York, April 26, 2002.
  • Stock RG. Invited speaker. 13th international Prostate Cancer Update. Importance of brachytherapy dose long-term brachytherapy outcomes and Hormonal therapy, Brachytherapy and External Beam Irradiation in the treatment of high risk prostate cancer. Vail, Colorado. February 22, 2003
  • Stock RG. Co-Director and presenter at the 8th Annual Prostate Cancer Symposium. CME Accredited course. Scottsdale, Arizona, February 26-March 1, 2003.
  • Stock RG. Invited speaker. 14th International Prostate Cancer Update. Erectile function and brachytherapy. Vail CO. Feb 5 –8, 2004.
  • Stock RG. Co-Director and presenter at the 9th Annual Prostate Cancer Symposium. CME Accredited course. Scottsdale, Arizona, March 4 –8, 2004.
  • Stock RG. Invited speaker. Seattle Prostate Institute Annual Advanced Brachytherapy Meeting. Invited speaker. Seattle, WA. April 1- 3, 2004.
  • Stock RG. Invited speaker. Normal tissue tolerance for prostate brachytherapy. Combined American Brachytherapy Society – GEC ESTRO annual meeting. Barcelona, Spain. May 12 – May 14, 2004.
  • Stock RG. Alpha/ beta ratio and biologically effective dose derived from the combined therapies of external beam and implant for prostate cancer. Spring Symposium of the Radiological and Medical Physics Society of New York. May 22, 2004.
  • Stock RG. Invited speaker. American Brachytherapy Society – School of Brachytherapy. Chicago, IL. June 17 – 18, 2004.
  • Stock RG. Invited speaker. Is there a correct way to perform prostate brachytherapy. New perspectives on prostate cancer. CME course. Roslyn New York, November 12, 2004.
  • Stock RG. Co-Director and presenter at the 10th Annual Prostate Cancer Symposium. CME Accredited course. Scottsdale, Arizona, March 4 –8, 2005.
  • Stock RG. Role of hormonal therapy in the brachytherapy management of prostate cancer. Invited speaker. American brachytherapy annual meeting. San Francisco CA. June 1 – 4, 2005.
  • Stock RG. Course director. 11th Annual Prostate cancer Symposium. CME course. Scottsdale, AZ, March 5 –7, 2006
  • Stock RG. Invited speaker. 9th Annual Prostate Brachytherapy Conference. Seattle , CME course . WA. March 24-25, 2006.
  • Stock RG. Invited speaker. International Prostate Brachytherapy Conference. Memorial Sloan Kettering Cancer Center. CME course. June 22 –23, 2006.
  • Stock RG. American Brachytherapy Society – School of Prostate Brachytherapy. CME course. Chicago, IL. July 21 –22, 2006.
  • Stock RG. Patterns of failure following the brachytherapy management of prostate cancer. ASTRO oral presentation. Philadelphia, PA. November 7, 2006.
  • Stock RG. Prostate brachytherapy clinical update. Berkshire Medical Center, Pittsfield, MA. January 18, 2007.
  • Stock RG. Course co-director. 12th Annual Prostate Cancer Symposium. CME Accredited course. Scottsdale, Arizona, March 1-4, 2007.
  • Stock RG. Prostate brachytherapy. Spanish Urology Course. CME accredited. Mount Sinai Hospital, New York, NY. April 27, 2007.
  • Stock RG. Principles of Prostate Brachytherapy. New York Roentgen Society Annual Spring Meeting. CME accredited. New York, NY. April 27th, 2007.
  • Stock RG. American Brachytherapy Annual meeting – Speaker – 1) real time seed implant technique, 2) salvage brachytherapy, 3) panel on post-op dosimetry. Chicago, IL. April 28th – May 1, 2007.
  • Stock RG. Update on prostate brachytherapy. ASTRO satellite symposium. Los angeles, CA. September 2007.
  • Stock RG. Co-Course director. 13th Annual Prostate Cancer Symposium. CME course. Scottsdale, AZ, February 28 -March 2, 2008.
  • Stock RG. Importance of BED in prostate brachytherapy. Seattle Prostate Institute Annual Advanced Brachytherapy Meeting. CME course. Seattle, WA. April 18, 2008.
  • Stock RG. Trimodality therapy for high risk prostate cancer. Seattle Prostate Institute Annual Advanced Brachytherapy Meeting. CME course. Seattle, WA. April 19, 2008.
  • Stock RG. Invited speaker. Normal tissues tolerance cut-points for prostate brachytherapy. American Brachytherapy Annual Meeting. Boston, MA. May 6, 2008.
  • Stock RG. Invited speaker. Grand Rounds. Robert Wood Johnson Cancer Center. The importance of implant quality in the brachytherapy management of prostate cancer. New Brunswick, NJ. October 14th, 2008.
  • Stock RG. Visiting Professor and speaker. Tokyo Medical Center, Tokyo, Japan 12/5/09 – 12/10/09.
  • Stock RG. Importance of brachytherapy in the management of prostate cancer. Florida radiation Oncology Group annual Prostate cancer Meeting. Jacksonville, FL Febuary 12, 2009.
  • Stock RG. Co-Course director. 14th Annual Prostate Cancer Symposium. CME course. Scottsdale, AZ, March 5 -March 9, 2009
  • Stock RG. Annual Meeting of Ireland and UK Brachytherapy Society. Keynote Speaker. Lessons learned from 19 years of brachytherapy experience. Trimodality therapy for high risk prostate cancer. Galway, Ireland April 17 – 19, 2009.
  • Stock RG. Urology grand rounds. Adjuvant and salvage radiation therapy following prostatectomy. September 17, 2009.
  • Stock RG. Co-Course director. 15th Annual Prostate Cancer Symposium. CME course. Scottsdale, AZ, March 4 – 7, 2010.
  • Stock RG. Invited speaker American brachytherapy Society Annual Meeting. Real time Brachytherapy technique. Atlanta, GA, April 30, 2010.
  • Stock RG. Speaker at American Urological Association annual meeting. Symposium on high risk prostate cancer. San Francisco, CA, June 1, 2010.
  • Stock RG. Invited speaker. American Brachytherapy School of Prostate Brachytherapy. Chicago, IL, July 9 – 10, 2010.
 

MEDIA RESOURCE EDUCATIONAL MATERIAL:

  1. Stock RG: Interactive ultrasound-guided transperineal prostate video presentation. Urologic Surgery Motion Picture Session. American College of Surgeons 82nd Annual Clinical Congress. San Francisco, California. October 1996.
  2. Stock RG. Prostate cancer update. Conversations with urologic oncology leaders. Bridging the gap between research and patient care. Editor: Neil Love. Faculty: Mark Soloway, Richard Stock, Mitchel Benson. CD ROM and audio material. CME certified. 2003.